The study found that 24% of those who contacted a center specializing in rare kidney diseases would have gone undiagnosed if they had not reached out directly via the center's website.
The internet is a powerful tool for families looking to make a self-diagnosis of rare diseases, according to a recently published study, which used the example of several rare inherited kidney diseases to demonstrate its effectiveness in helping patients find a correct diagnosis. But the study also highlighted certain aspects of disparities in care, as those making self-referrals were largely white and had high income.
Researchers analyzed 665 referrals made from 1996 to 2017 to a Wake Forest School of Medicine research center specializing in autosomal dominant tubulointerstitial kidney disease (ADTKD), a group of rare inherited conditions that gradually cause kidneys to stop functioning.
Among the referrals, 40% were from healthcare providers at academic medical centers, 33% were from nonacademic practitioners, and 27% were self-referrals from individuals or family members with concerns about, but no diagnosis of, inherited kidney disease. Those individuals and family members contacted the center directly through its website without guidance or assistance from other medical professionals. Genetic testing results were positive (indicating the presence of ADTKD) in 27% of the cases referred by academic centers, 25% of those referred by nonacademic providers, and 24% of those who contacted the center directly.
The 24% represented 42 families and 116 individuals who otherwise would have gone undiagnosed if they had not contacted the center, Anthony J. Bleyer, MD, professor of nephrology at the medical school, said in a statement.
"Rare diseases, especially inherited ones, are often not correctly diagnosed by primary care physicians and even specialists because they are so uncommon, and a provider who does have expertise may be located very far from the patient," said Bleyer, the study's lead author. "While online searches can frequently fail to provide relevant or correct health information, the internet does offer those with rare disorders a way to find the rare specialists interested in a particular condition and obtain accurate information about it."
One of the study's limitations is that it examined data from only 1 center specializing in a single rare disorder.
In addition, the study highlights the consequences of the digital divide as well as racial and socioeconomic disparities in healthcare. Virtually all of those (99%) contacting the center directly were white, and had significantly higher income than the rest of the United States. The median income of the zip codes from the site of referrals was $77,316, compared with the 2010 US median household income of $49,445.34
While there is no evidence to suggest that the variants causing ADTKD would create a difference in prevalence among races, there were no self referrals from black patients, and few individuals from non-English speaking countries, the researchers wrote.
Even though kidney disease is much more prevalent in blacks, the researchers noted that they are more likely to have misgivings about research and also be less likely to trust the medical profession generally. Since black patients were less likely to be referred by their providers, decreased access to providers may also be a factor. In addition, the high prevalence of chronic kidney disease in blacks may have contributed to decreased consideration of a genetic diagnosis.
Besides providing an improved interpersonal experience with patients, screening genetic disorders in patients in dialysis centers would enhance access to individuals across the digital divide, the researchers reported.
The authors noted the general difficulties in obtaining a correct diagnosis for a rare disease. Primary care physicians have time constraints, a lack of specific knowledge, a lack of interest, or “a belief that securing the diagnosis will not alter the patient’s treatment plan.” Specialists, too, may stop searching for answers when nothing turns up.
Centers should consider improving direct access to families if they work in rare disease areas, the authors said.
Reference
Bleyer AJ, Kidd K, Robins V, et al. Outcomes of patient self-referral for the diagnosis of several rare inheritied kidney diseases [published online July 24, 2019]. Genet. Med. doi: 10.1038/s41436-019-0617-8.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More